首页 > 最新文献

Australian Prescriber最新文献

英文 中文
Australian clinical guideline for deprescribing in older people. 澳大利亚老年人开处方临床指南。
IF 4.2 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.055
{"title":"Australian clinical guideline for deprescribing in older people.","authors":"","doi":"10.18773/austprescr.2025.055","DOIUrl":"https://doi.org/10.18773/austprescr.2025.055","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"211"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Top 10 drugs 2024-25. 2024- 2025年十大药物。
IF 4.2 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.057
{"title":"Top 10 drugs 2024-25.","authors":"","doi":"10.18773/austprescr.2025.057","DOIUrl":"https://doi.org/10.18773/austprescr.2025.057","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"210"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fenfluramine for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. 芬氟拉明治疗与Dravet综合征和lenox - gastaut综合征相关的癫痫发作。
IF 4.2 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.054
{"title":"Fenfluramine for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome.","authors":"","doi":"10.18773/austprescr.2025.054","DOIUrl":"10.18773/austprescr.2025.054","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"214-215"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Near-fatal reaction associated with cotrimoxazole, metformin and kidney impairment. 与复方新诺明、二甲双胍和肾脏损害相关的近乎致命的反应。
IF 4.2 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.053
John Marley
{"title":"Near-fatal reaction associated with cotrimoxazole, metformin and kidney impairment.","authors":"John Marley","doi":"10.18773/austprescr.2025.053","DOIUrl":"10.18773/austprescr.2025.053","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"208-209"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Australian Prescriber peer reviewers, 2023 to 2025. 澳大利亚处方同行评审，2023年至2025年。
IF 4.2 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.051
{"title":"<i>Australian Prescriber</i> peer reviewers, 2023 to 2025.","authors":"","doi":"10.18773/austprescr.2025.051","DOIUrl":"https://doi.org/10.18773/austprescr.2025.051","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"216"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fifty years of Australian Prescriber - continuing a proud tradition of trusted, independent information. 五十年的澳大利亚处方-继续一个值得骄傲的传统，值得信赖的，独立的信息。
IF 4.2 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.056
Michael Kidd
{"title":"Fifty years of <i>Australian Prescriber</i> <b>-</b> continuing a proud tradition of trusted, independent information.","authors":"Michael Kidd","doi":"10.18773/austprescr.2025.056","DOIUrl":"10.18773/austprescr.2025.056","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"192-193"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calcifediol high-strength formulation for vitamin D deficiency. 钙化二醇高强度配方，用于维生素D缺乏。
IF 4.2 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.050
{"title":"Calcifediol high-strength formulation for vitamin D deficiency.","authors":"","doi":"10.18773/austprescr.2025.050","DOIUrl":"10.18773/austprescr.2025.050","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"212-213"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypertension - a major modifiable and undertreated risk factor. 高血压-一个主要的可改变和治疗不足的危险因素。
IF 4.2 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.049
Charlotte Hespe, Nigel Stocks, Mark Nelson
{"title":"Hypertension - a major modifiable and undertreated risk factor.","authors":"Charlotte Hespe, Nigel Stocks, Mark Nelson","doi":"10.18773/austprescr.2025.049","DOIUrl":"10.18773/austprescr.2025.049","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"194-196"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Injectable drugs for weight management. 用于控制体重的注射药物。
IF 4.2 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.052
Natasha Yates, Terri-Lynne South

Obesity management is complex; medications must be used in conjunction with behavioural changes and monitoring by health professionals. Injectable drugs for weight management include glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. liraglutide, semaglutide) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (e.g. tirzepatide). These drugs contribute to weight loss by mimicking the incretin hormones GLP-1 and GIP to reduce appetite, change food enjoyment, slow stomach emptying and stimulate insulin release. Regaining weight is common when these drugs are stopped, so they usually need to be continued long term. Relatively minor gastrointestinal issues are common. There is also a small but real risk of more serious adverse effects, including gallstones and pancreatitis. It is important to monitor mental health, as these drugs can change a patient's relationship with food, and they may be misused by those without obesity.

肥胖管理是复杂的；药物的使用必须与行为改变和卫生专业人员的监测相结合。用于体重管理的注射药物包括胰高血糖素样肽-1 （GLP-1）受体激动剂（如利拉鲁肽、半马鲁肽）和双葡萄糖依赖性胰岛素性多肽(GIP)/GLP-1受体激动剂（如替西肽）。这些药物通过模拟肠促胰岛素激素GLP-1和GIP来减少食欲，改变食物的享受，减缓胃排空和刺激胰岛素的释放，从而有助于减肥。停药后体重反弹是很常见的，所以通常需要长期服用。相对轻微的胃肠道问题是常见的。也有一个小但真实的风险更严重的副作用，包括胆结石和胰腺炎。监测心理健康很重要，因为这些药物可以改变病人与食物的关系，而且它们可能被那些没有肥胖的人滥用。
{"title":"Injectable drugs for weight management.","authors":"Natasha Yates, Terri-Lynne South","doi":"10.18773/austprescr.2025.052","DOIUrl":"10.18773/austprescr.2025.052","url":null,"abstract":"<p><p>Obesity management is complex; medications must be used in conjunction with behavioural changes and monitoring by health professionals. Injectable drugs for weight management include glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. liraglutide, semaglutide) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists (e.g. tirzepatide). These drugs contribute to weight loss by mimicking the incretin hormones GLP-1 and GIP to reduce appetite, change food enjoyment, slow stomach emptying and stimulate insulin release. Regaining weight is common when these drugs are stopped, so they usually need to be continued long term. Relatively minor gastrointestinal issues are common. There is also a small but real risk of more serious adverse effects, including gallstones and pancreatitis. It is important to monitor mental health, as these drugs can change a patient's relationship with food, and they may be misused by those without obesity.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"197-202"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testing for human immunodeficiency virus. 人类免疫缺陷病毒测试。
IF 4.2 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2025-12-01 DOI: 10.18773/austprescr.2025.048
Louise Owen, Ian Woolley

Testing for human immunodeficiency virus (HIV) is recommended for individuals with behavioural or epidemiological risk factors, and those who present with clinical indicator conditions. Routine testing is recommended in pregnancy and as part of symptomatic and asymptomatic sexually transmissible infection check-ups. In Australia, laboratories primarily use combined HIV antibody and antigen tests for diagnostic testing. A reactive test is followed by a laboratory confirmatory test. Clinicians should consider whether the person is within the testing window period when interpreting results. On receipt of a confirmed HIV-positive result, healthcare providers must discuss the result and contact tracing with the patient, and ideally refer them to specialised services, including an HIV care provider.

建议对具有行为或流行病学危险因素的个人以及有临床指标条件的个人进行人类免疫缺陷病毒（艾滋病毒）检测。建议在怀孕期间进行常规检测，并作为有症状和无症状性传播感染检查的一部分。在澳大利亚，实验室主要使用艾滋病毒抗体和抗原联合检测进行诊断检测。反应性试验之后是实验室确认性试验。临床医生在解释结果时应考虑患者是否处于检测窗口期。在收到确认的艾滋病毒阳性结果后，医疗保健提供者必须与患者讨论结果和接触者追踪，并最好将其转介到专门服务机构，包括艾滋病毒护理提供者。
{"title":"Testing for human immunodeficiency virus.","authors":"Louise Owen, Ian Woolley","doi":"10.18773/austprescr.2025.048","DOIUrl":"10.18773/austprescr.2025.048","url":null,"abstract":"<p><p>Testing for human immunodeficiency virus (HIV) is recommended for individuals with behavioural or epidemiological risk factors, and those who present with clinical indicator conditions. Routine testing is recommended in pregnancy and as part of symptomatic and asymptomatic sexually transmissible infection check-ups. In Australia, laboratories primarily use combined HIV antibody and antigen tests for diagnostic testing. A reactive test is followed by a laboratory confirmatory test. Clinicians should consider whether the person is within the testing window period when interpreting results. On receipt of a confirmed HIV-positive result, healthcare providers must discuss the result and contact tracing with the patient, and ideally refer them to specialised services, including an HIV care provider.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"48 6","pages":"203-207"},"PeriodicalIF":4.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12711353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Australian Prescriber
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1